Detection of minimal residual disease (MRD) has proven to provide independent prognostic
information for treatment stratification in several types of leukemias such as childhood acute …

Prospective studies on the detection of minimal residual disease (MRD) in acute leukemia
patients have shown that large-scale MRD studies are feasible and that clinically relevant …

A unique mRNA produced in leukemic cells from at (15; 17) acute promyelocytic leukemia
(APL) patient encodes a fusion protein between the retinoic acid receptor a (RARa) and a …

Background All-trans-retinoic acid induces complete remission in acute promyelocytic
leukemia. However, it is not clear whether induction therapy with all-trans-retinoic acid is …

Acute promyelocytic leukemia is a clonal expansion of hematopoietic precursors blocked at
the promyelocytic stage. The differentiation block can be reversed by retinoic acid, which …

Discoveries in cancer research are rarely so exceptional that they both cause immediate
changes in the treatment of patients and dramatically advance our understanding of the …

Acute leukaemias are characterized by recurring chromosomal aberrations and gene
mutations that are crucial to disease pathogenesis. It is now evident that epigenetic …

Acute promyeiocytic leukemia (APL) is associated with at (15; 17) transiocation that creates
the promyelocyte-retinoic acid receptor a (PML-RARa) fusion gene. immunohistochemistry …

The PML gene is fused to the retinoic acid receptor α (RARα) gene in chromosomal
translocations associated with acute promyelocytic leukemia (APL). Ablation of murine PML …

Acute promyelocytic leukaemia (APL), associated with chromosomal translocations
involving the retinoic acid receptor α gene (RARA) and the PML gene, is sensitive to retinoic …